Net Revenues Increased by 11% to U$ 86 million, with Adjusted EBITDA Up 15% Year-Over-Year to $9 Million...
This acquisition reaffirms Procaps Groups’ strategy to become one of the fastest growing pharmaceutical organizations in Latin America With FY2021 Net...
Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the fourth quarter and fiscal year ended...
Procaps Group (NASDAQ: PROC), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced a new capacity expansion plan in the United States and Colombia for its Funtrition...
Procaps Group (NASDAQ: PROC), a leading integrated international healthcare and pharmaceutical company, today announced the appointment of Melissa Angelini as Investor Relations Director, effective February...
Procaps Group (NASDAQ: PROC), a leading integrated international healthcare and pharmaceutical company, today announced the closing of an asset purchase agreement to acquire an 86,000 sq. ft. pharmaceutical...
Procaps Group (NASDAQ: PROC), a leading integrated international healthcare and pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2021.